ICER rates Astel­las' po­ten­tial menopausal symp­tom drug as promis­ing at about $2K per year

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) on Thurs­day pub­lished a new ev­i­dence re­port for Astel­las Phar­ma’s fe­zo­line­tant, rec­om­mend­ing that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.